Motor Cortex Stimulation

Aetna considers motor cortex stimulation experimental and investigational and therefore not covered for treatment of amyotrophic lateral sclerosis, autism spectrum disorder, cerebral palsy, dysphagia, and chronic refractory pain conditions (e.g., central pain syndromes, complex regional pain syndrome, neuropathic orofacial pain, peripheral neuropathic pain, phantom limb pain, thalamic pain, trigeminal neuropathic pain). Key requirement: its investigational designation means it is excluded from coverage for these (and other unspecified) indications until sufficient evidence demonstrates safety and effectiveness.

"Aetna considers motor cortex stimulation experimental and investigational for the treatment of the following indications (not an all-inclusive list): Amyotrophic lateral sclerosis"

Sign up to see full coverage criteria, indications, and limitations.